Stockreport

Capricor signals potential commercialization of Deramiocel with $318M cash balance and FDA review milestone [Seeking Alpha]

Capricor Therapeutics, Inc.  (CAPR) 
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: capricor.com/investors
PDF Linda Marbán, Co-Founder, President, CEO & Director, stated the company's focus is on advancing Deramiocel for potential approval in Duchenne muscular dystrophy (DMD) a [Read more]